Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET
Company Participants
Ian Karp - Senior Vice President, Investor Relations & Corporate Communications
John Leonard - President & Chief Executive Officer
Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer
Ed Dulac - Executive Vice President & Chief Financial Officer
Conference Call Participants
Mary Kate Davis - Bank of America
Dae Gon Ha - Stifel
Joseph Thome - TD Cowen
Luca Issi - RBC
Gena Wang - Barclays
Maury Raycroft - Jefferies
Mani Foroohar - Leerink
Rick Bienkowski - Cantor Fitzgerald
Jay Olson - Oppenheimer
Timor Vanicus - Raymond James
Silvan Tuerkcan - Citizens JMP
William Pickering - Bernstein
Myles Minter - William Blair
David Lebowitz - Citi
Operator
Good morning, and welcome to Intellia Therapeutics’ Second Quarter 2024 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. As a reminder, all participants are currently in listen-only mode. [Operator Instructions]
I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Ian Karp
Thank you, operator and good morning everyone. Welcome to Intellia Therapeutics second quarter 2024 earnings call. Earlier this morning, Intellia issued a press release outlining the company's progress this quarter, as well as topics for discussion on today's call. This release can be found on the Investors and Media section of Intellia's website at intelliatx.com. This call is being broadcast live and a replay will be archived on the company's website.
At this time, I'd like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for discussion of potential risks and uncertainties. All information presented on this call is current as of today and Intellia undertakes no duty to update this information unless required by law.
Joining me from Intellia are John Leonard, Chief Executive Officer; Laura Sepp-Lorenzino, Chief Scientific Officer; Ed Dulac, Chief Financial Officer. Also in the room and available for the Q&A is Liron Walsh, Head of Development for In vivo Programs. Our Chief Medical Officer, David Lebwohl is unable to join us today, but he will be participating in upcoming investor conferences.